Muscle-Invasive Bladder Cancer: Difference between revisions

Line 71:

*** Randomized to neoadjuvant CMV vs. cystectomy alone

*** [https://pubmed.ncbi.nlm.nih.gov/21502557/ International Collaboration of Trialists.] "International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial." Journal of Clinical Oncology 29.16 (2011): 2171.

* '''2005 meta-analysis''' combining individual patient data from 9 trials (these 2 trials with 9 phase II trials) involving 3005 patients comparing neoadjuvant chemotherapy plus local treatment with the same local treatment alone found that '''neoadjuvant chemotherapy was associated with improved:'''

* '''2005 meta-analysis''' combining individual patient data from 9 trials (these 2 trials with 9 phase II trials) involving 3005 patients comparing neoadjuvant chemotherapy plus local treatment with the same local treatment alone found that '''neoadjuvant chemotherapy was associated with improved:'''

** '''5-year OS: absolute benefit 5%'''

** '''5-year OS: absolute benefit 5%'''

** '''5-year DFS: absolute benefit 9%'''

** '''5-year DFS: absolute benefit 9%'''

** '''Pathologic complete response (pT0) rate of 30-40% compared to 15% (SWOG trial results) without NAC'''

** Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. “Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.” Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6. Epub 2005 Apr 21.

@@ Line 71: / Line 71: @@
 *** Randomized to neoadjuvant CMV vs. cystectomy alone
 *** [https://pubmed.ncbi.nlm.nih.gov/21502557/ International Collaboration of Trialists.] "International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial." Journal of Clinical Oncology 29.16 (2011): 2171.
-* '''2005 meta-analysis''' combining individual patient data from 9 trials (these 2 trials with 9 phase II trials) involving 3005 patients comparing neoadjuvant chemotherapy plus local treatment with the same local treatment alone found that '''neoadjuvant chemotherapy was associated with improved:'''
+* '''2005 meta-analysis''' combining individual patient data from 9 trials (these 2 trials with 9 phase II trials) involving 3005 patients comparing neoadjuvant chemotherapy plus local treatment with the same local treatment alone found that '''<span style="color:#ff0000">neoadjuvant chemotherapy was associated with improved:</span>'''
-** '''5-year OS: absolute benefit 5%'''
+** '''<span style="color:#ff0000">5-year OS: absolute benefit 5%</span>'''
-** '''5-year DFS: absolute benefit 9%'''
+** '''<span style="color:#ff0000">5-year DFS: absolute benefit 9%</span>'''
 ** '''Pathologic complete response (pT0) rate of 30-40% compared to 15% (SWOG trial results) without NAC'''
 ** Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. “Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.” Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6. Epub 2005 Apr 21.